HA
PRLD icon

HHLR Advisors’s Prelude Therapeutics PRLD Stock Holding History

HHLR Advisors’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-583,333
Closed -$3.86M – 72
2022
Q3 		$3.86M Hold
583,333
– – 0.1% 45
2022
Q2 		$3.04M Hold
583,333
– – 0.07% 52
2022
Q1 		$4.03M Hold
583,333
– – 0.08% 49
2021
Q4 		$7.26M Hold
583,333
– – 0.11% 58
2021
Q3 		$18.2M Hold
583,333
– – 0.24% 46
2021
Q2 		$16.7M Sell
583,333
-43,169
-7% -$1.54M 0.17% 59
2021
Q1 		$27.1M Sell
626,502
-123,498
-16% -$8.19M 0.27% 41
2020
Q4 		$53.7M Hold
750,000
– – 0.43% 33
2020
Q3 		$22.6M Buy
+750,000
New +$21.2M 0.17% 46

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

HHLR Advisors's PRLD Position: Q4 2022 in Review

HHLR Advisors sold out of Prelude Therapeutics (PRLD) in Q4 2022, closing a stake of 583,333 shares — an estimated $3.86M sold.

HHLR Advisors first reported a position in PRLD in Q3 2020 and held it in 9 quarters. The position peaked at $53.7M in Q4 2020. 60 funds tracked by Wall St. Rank hold PRLD as of Q4 2022.

  • HHLR Advisors reported no remaining Prelude Therapeutics position as of Q4 2022 after selling out during the quarter.
  • HHLR Advisors sold 583,333 Prelude Therapeutics shares in Q4 2022, an estimated $3.86M.
  • HHLR Advisors first reported a position in Prelude Therapeutics in Q3 2020 and held it in 9 quarters.
  • HHLR Advisors's Prelude Therapeutics position peaked at $53.7M in Q4 2020.
  • 60 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2022.

Based on HHLR Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.